Ryota Masuzaki, Ph.D., M.D.

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson SC, Schuppan D (2013) Hepatology 58(5): 1667-80
   › Primary publication · 23729316 (PubMed)
2. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. Tateishi R, Shiina S, Akahane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K (2013) PLoS One 8(4): e59040
   › Primary publication · 23593129 (PubMed) · PMC3625228 (PubMed Central)
3. Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon-α and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. Hikita H, Enooku K, Satoh Y, Yoshida H, Nakagawa H, Masuzaki R, Tateishi R, Soroida Y, Sato M, Suzuki A, Gotoh H, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H (2013) Hepatol Res 43(10): 1005-12
   › Primary publication · 23356977 (PubMed)
4. Scar formation and lack of regeneration in adult and neonatal liver after stromal injury. Masuzaki R, Zhao SR, Csizmadia E, Yannas I, Karp SJ (2013) Wound Repair Regen 21(1): 122-30
   › Primary publication · 23228176 (PubMed)
5. New serum markers of hepatocellular carcinoma. Masuzaki R, Karp SJ, Omata M (2012) Semin Oncol 39(4): 434-9
   › Primary publication · 22846860 (PubMed)
6. Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients. Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H (2013) J Gastroenterol 48(3): 366-73
   › Primary publication · 22790352 (PubMed)
7. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H (2012) J Hepatol 57(2): 330-6
   › Primary publication · 22521349 (PubMed)
8. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K (2012) World J Gastroenterol 18(12): 1385-90
   › Primary publication · 22493553 (PubMed) · PMC3319966 (PubMed Central)
9. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K (2012) J Gastroenterol 47(10): 1152-9
   › Primary publication · 22438097 (PubMed)
10. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K (2012) J Gastroenterol 47(4): 477-85
    › Primary publication · 22200940 (PubMed)
11. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K (2012) Am J Gastroenterol 107(4): 569-77; quiz 578
    › Primary publication · 22158026 (PubMed) · PMC3321437 (PubMed Central)
12. Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K (2012) Hepatol Int 6(3): 639-45
    › Primary publication · 22020826 (PubMed)
13. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K (2012) J Gastroenterol 47(1): 71-8
    › Primary publication · 21935635 (PubMed)
14. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y (2011) Cancer Epidemiol Biomarkers Prev 20(10): 2204-11
    › Primary publication · 21876190 (PubMed)
15. Stiffness of the first annular pulley in normal and trigger fingers. Miyamoto H, Miura T, Isayama H, Masuzaki R, Koike K, Ohe T (2011) J Hand Surg Am 36(9): 1486-91
    › Primary publication · 21802865 (PubMed)
16. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. Shimada M, Yoshida S, Masuzaki R, Schuppan D (2012) J Hepatol 56(1): 299-300
    › Primary publication · 21718671 (PubMed)
17. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, Koike K, Omata M (2011) Hepatol Int 5(3): 767-73
    › Primary publication · 21484129 (PubMed)
18. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K (2011) Cancer 117(19): 4475-83
    › Primary publication · 21437884 (PubMed)
19. Autotaxin as a novel serum marker of liver fibrosis. Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y (2011) Clin Chim Acta 412(13-14): 1201-6
    › Primary publication · 21419756 (PubMed)
20. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K (2011) Int J Cancer 129(9): 2226-35
    › Primary publication · 21170963 (PubMed)
21. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, Koike K (2011) Liver Int 31(2): 197-205
    › Primary publication · 21159122 (PubMed)
22. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K (2011) J Gastroenterol Hepatol 26(4): 759-64
    › Primary publication · 21054516 (PubMed)
23. Increased liver elasticity in patients with biliary obstruction. Yashima Y, Tsujino T, Masuzaki R, Nakai Y, Hirano K, Tateishi R, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M (2011) J Gastroenterol 46(1): 86-91
    › Primary publication · 20814804 (PubMed)
24. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Masuzaki R, Yoshida H, Omata M (2010) Oncology : 17-23
    › Primary publication · 20616579 (PubMed)
25. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Masuzaki R, Yoshida H, Omata M (2010) Dig Liver Dis : S281-6
    › Primary publication · 20547315 (PubMed)
26. Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki A, Koike Y, Yatomi Y, Omata M, Koike K (2010) J Gastroenterol 45(8): 876-84
    › Primary publication · 20339877 (PubMed)
27. Staging systems: is there a surgical staging and a medical one?: hepatologist's perspective. Masuzaki R, Yoshida H, Tateishi R, Omata M (2010) J Hepatobiliary Pancreat Sci 17(4): 440-2
    › Primary publication · 19902138 (PubMed)
28. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. Goto E, Tateishi R, Shiina S, Masuzaki R, Enooku K, Sato T, Ohki T, Kondo Y, Goto T, Yoshida H, Omata M (2010) J Clin Gastroenterol 44(5): 374-80
    › Primary publication · 19809357 (PubMed)
29. Assessing liver tumor stiffness by transient elastography. Masuzaki R, Tateishi R, Yoshida H, Sato T, Ohki T, Goto T, Yoshida H, Sato S, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M (2007) Hepatol Int 1(3): 394-7
    › Primary publication · 19669335 (PubMed) · PMC2716830 (PubMed Central)
30. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Yoshida H, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, Tateishi R, Goto T, Shiina S, Kawabe T, Omata M (2008) Hepatol Int 2(1): 89-94
    › Primary publication · 19669283 (PubMed) · PMC2716870 (PubMed Central)
31. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, Goto T, Kanai F, Obi S, Kato N, Shiina S, Kawabe T, Omata M (2009) Hepatol Int 3(4): 544-50
    › Primary publication · 19669240 (PubMed) · PMC2790585 (PubMed Central)
32. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M (2009) Int J Cancer 125(10): 2264-9
    › Primary publication · 19585572 (PubMed)
33. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M (2010) J Viral Hepat 17(2): 91-7
    › Primary publication · 19566786 (PubMed)
34. Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Masuzaki R, Yamashiki N, Sugawara Y, Yoshida H, Tateishi R, Tamura S, Kaneko J, Hasegawa K, Kokudo N, Makuuchi M, Omata M (2009) Scand J Gastroenterol 44(9): 1115-20
    › Primary publication · 19562623 (PubMed)
35. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M (2009) Hepatology 49(6): 1954-61
    › Primary publication · 19434742 (PubMed)
36. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M (2008) Best Pract Res Clin Gastroenterol 22(6): 1137-51
    › Primary publication · 19187872 (PubMed)
37. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M (2009) Gut 58(6): 839-44
    › Primary publication · 19174415 (PubMed)
38. Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. Tateishi R, Shiina S, Ohki T, Sato T, Masuzaki R, Imamura J, Goto E, Goto T, Yoshida H, Obi S, Sato S, Kanai F, Yoshida H, Omata M (2009) J Gastroenterol : 142-6
    › Primary publication · 19148809 (PubMed)
39. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T, Yoshida H, Kanai F, Hamamura K, Obi S, Yoshida H, Omata M (2008) Am J Gastroenterol 103(12): 3057-62
    › Primary publication · 19086957 (PubMed)
40. [Estimation of the incidence rate of NASH-related HCC in Japan]. Yoshida H, Tateishi R, Shiina S, Sato T, Ohki T, Masuzaki R, Imamura J, Goto T, Omata M (2008) Nihon Shokakibyo Gakkai Zasshi 105(11): 1577-83
    › Primary publication · 18987441 (PubMed)
41. Comparison of liver biopsy and transient elastography based on clinical relevance. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Goto T, Yoshida H, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M (2008) Can J Gastroenterol 22(9): 753-7
    › Primary publication · 18818788 (PubMed) · PMC2661279 (PubMed Central)
42. Treatment of hepatocellular carcinoma. Masuzaki R, Omata M (2008) Indian J Gastroenterol 27(3): 113-22
    › Primary publication · 18787282 (PubMed)
43. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Kanda M, Tateishi R, Yoshida H, Sato T, Masuzaki R, Ohki T, Imamura J, Goto T, Yoshida H, Hamamura K, Obi S, Kanai F, Shiina S, Omata M (2008) Liver Int 28(9): 1256-63
    › Primary publication · 18710423 (PubMed)
44. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, Kato N, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M (2008) J Clin Gastroenterol 42(7): 839-43
    › Primary publication · 18668703 (PubMed)
45. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M (2008) Clin Gastroenterol Hepatol 6(4): 459-64
    › Primary publication · 18387499 (PubMed)
46. Obesity did not diminish the efficacy of percutaneous ablation for hepatocellular carcinoma. Ohki T, Tateishi R, Shiina S, Sato T, Masuzaki R, Yoshida H, Kanai F, Obi S, Yoshida H, Omata M (2007) Liver Int 27(3): 360-7
    › Primary publication · 17355458 (PubMed)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword